Adagrasib
-
Adagrasib
structure -
-
CAS No:
2326521-71-3
-
Formula:
C32H35ClFN7O2
-
Chemical Name:
Adagrasib
-
Synonyms:
MRTX849;MRTX-849;MRTX 849;2-PIPERAZINEACETONITRILE, 4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR;2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-;2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile;MRTX849(Adagrasib);Adagrasib/MRTX-849;Adagrasib;4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR
- Categories:
-
CAS No:
Description
KRAS G12C Inhibitor MRTX849 is an orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration MRTX849 covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
MRTX-849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favourable drug-like properties, modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signalling. MRTX-849 demonstrated pronounced tumour regression in 17 of 26 (65%) KRASG12C-positive cell line- and patient-derived xenograft models from multiple tumour types, and objective responses have been observed in patients with KRASG12C-positive lung and colon adenocarcinomas[1].
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Class: non-kinase; Treatment: KRAS(G12C) NSCLC; Other name: MRTX849; Elimination half-life: 24 h; Protein binding = 98.3%
Characteristics
1.295±0.06 g/cm3(Predicted)
860.2±75.0 °C(Predicted)
9.31±0.40(Predicted)
Store at -20°C
Drug Information
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile
Recommended Suppliers of Adagrasib
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
CN
2 YRS
Business licensedTrader Supplier of Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524,Milbemycin oxime,MeloxicamInquiryCAS No.: 2326521-71-3Grade: Reagent GradeContent: 99% -
CN
3 YRS
Business licensedTrader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE
Learn More Other Chemicals
-
3-(3-CHLOROPROPYLCARBAMOYL)BENZENEBORONIC ACID
874288-10-5
-
3-Pyridinecarboxylic acid, 2,6-dichloro-, ethyl ester
58584-86-4
-
(+)-Mesembrenone
468-54-2
-
1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (1:1) Formula
230615-52-8
-
(4-acetyloxyphenyl)-(4-acetyloxyphenyl)imino-oxidoazanium Formula
79030-44-7
-
1-(4-Methoxy-phenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde Formula
347331-30-0
-
2,2'-DIAMINODIPHENYL SULFIDE Structure
5873-51-8
-
AC-ARG-PHE-MET-TRP-MET-ARG-NH2 Structure
152274-65-2
-
What is 1,1-Dimethylethyl 2-bromo-2-methylpropanoate
23877-12-5
-
What is 1,3-Dichloro-2,4-difluorobenzene
36556-37-3